EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is ...

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 31.1% and a 54.0% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys ...

Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and ...

A week ago, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) came out with a strong set of first-quarter numbers that ...

Viridian Therapeutics (VRDN) priced upsized concurrent public offerings totaling $350M in gross proceeds, including $225M of ...

ZYUS Life Sciences Corporation (the "Company") , a clinical-stage life sciences company focused on the development and ...

Phase 3 trial data showed elegrobart significantly improved proptosis and diplopia in patients with moderate to severe chronic thyroid eye disease.

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

Here are the 10 worst-performing stocks so far in 2026 among companies that trade on major U.S. exchanges and have market ...

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.

Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027. Viridian ...

(NASDAQ:AVTX) were trading at $21.78, up almost 34%, or $5.52, on positive top-line results from the phase II Lotus trial evaluating the efficacy and safety of abdakibart in adults with moderate to ...